Evidence map›Paper›PMID 42782036›Full record

ArticleJACC. Case reports2026

TTR Variant p.Ala65Val Causing Early-Onset Hereditary Transthyretin Amyloidosis With Mixed Cardiac and Neuropathic Phenotype.

Javier Torres-Valencia, Sebastian Reyes-Villanes, Elder Quispe, Nelson Purizaca-Rosillo, Luisser Saavedra-Cordova, Mary M Araujo-Chumacero, Ricardo Román, Franklin Espinoza, Julio F Mamani, Miguel Reyes-Rocha

Abstract readCase Reports
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Javier Torres-ValenciaDepartment of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru. Electronic address: javier.tval@gmail.com.
Sebastian Reyes-VillanesDepartment of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Elder QuispeDepartamento de Neurología, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Instituto Nacional de Nervio y Músculo, Lima, Peru; Clinica Internacional, Lima, Peru.
Nelson Purizaca-RosilloServicio de Genética, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Luisser Saavedra-CordovaDepartment of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Mary M Araujo-ChumaceroEscuela Profesional de Medicina Humana, Universidad Privada Antenor Orrego, Trujillo, Peru; Instituto Nacional de Nervio y Músculo, Lima, Peru.
Ricardo RománDivision of Cardiology, Cayetano Heredia National Hospital, Lima, Peru.
Franklin EspinozaDepartment of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Servicio de Medicina Nuclear, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Julio F MamaniServicio de Medicina Nuclear, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Miguel Reyes-RochaDepartment of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVariant transthyretin amyloidosis (ATTRv) remains undercharacterized in Latin America, with limited awareness of its regional mutational diversity. CASE SUMMARY: A 48-year-old Peruvian man presented with syncope, exertional dyspnea, weight loss, and lower extremity paresthesia. Multimodality evaluation demonstrated severe infiltrative cardiomyopathy, small fiber and autonomic neuropathy, and peripheral nerve hypertrophy. Genetic testing identified a heterozygous pathogenic p.Ala65Val transthyretin variant, confirming ATTRv. No transthyretin-targeting therapies are currently accessible in Peru. DISCUSSION: To our knowledge, only 1 prior case harboring this variant has been reported, in a European patient with a late-onset presentation. Our patient exhibited an early-onset mixed cardiac and neuropathic phenotype, broadening the clinical spectrum of this rare variant. TAKE-HOME MESSAGE: This case highlights the phenotypic diversity of ATTRv and underscores the critical unmet need for disease-modifying therapy access and greater inclusion of Latin American patients in clinical trials.

Indexed as

chronic heart failureechocardiographygenetic disorders

Identifiers

PMID42782036
PMCPMC13616546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.